AbbVie completes $10.9 billion Apogee acquisition
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics and reaffirmed 2026 adjusted diluted EPS guidance.
AbbVie completed the $10.9 billion acquisition of Apogee Therapeutics and reaffirms its 2026 adjusted diluted EPS guidance.Key Highlights:Original SEC Filing: AbbVie Inc. [ ABBV ] - 8-K - Sep.
03, 2026This is an AI-powered summary.
It may contain inaccuracies.
Consider verifying important informati…